Christina D. Drenberg, Ph.D.
Affiliations: | 2010 | Medical Sciences | University of South Florida, Tampa, FL, United States |
Area:
Oncology, Cell Biology, PathologyGoogle:
"Christina Drenberg"Parents
Sign in to add mentor| Patricia A. Kruk | grad student | 2010 | University of South Florida | |
| (Angiostatic Regulators in Ovarian Cancer.) | ||||
BETA: Related publications
See more...
Publications
|
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
| Drenberg CD, Shelat A, Dang J, et al. (2019) A high-throughput screen indicates gemcitabine and JAK inhibitors may be useful for treating pediatric AML. Nature Communications. 10: 2189 |
| Pishas KI, Drenberg CD, Taslim C, et al. (2018) Therapeutic targeting of KDM1A/LSD1 in Ewing sarcoma with SP-2509 engages the endoplasmic reticulum stress response. Molecular Cancer Therapeutics |
| van Oosterwijk JG, Buelow DR, Drenberg CD, et al. (2017) Hypoxia-induced upregulation of BMX kinase mediates therapeutic resistance in acute myeloid leukemia. The Journal of Clinical Investigation |
| Drenberg C, Gibson AA, Pounds S, et al. (2017) OCTN1 is a high-affinity carrier of nucleoside analogs. Cancer Research |
| Drenberg CD, Buaboonnam J, Orwick SJ, et al. (2016) Evaluation of artemisinins for the treatment of acute myeloid leukemia. Cancer Chemotherapy and Pharmacology |
| Drenberg CD, Hu S, Li L, et al. (2016) ABCC4 Is a Determinant of Cytarabine-Induced Cytotoxicity and Myelosuppression. Clinical and Translational Science |
| Drenberg CD, Shelat A, Orwick SJ, et al. (2016) Abstract 4786: Integrated high-throughput screen to identify treatment leads for pediatric AML Cancer Research. 76: 4786-4786 |
| Dobrinski KP, Drenberg CD, Edelman JL, et al. (2015) Increased High Mobility Group Protein A2/SMAD3 Relates to Ovarian Cancer Progression Journal of Gynecology Research. 1 |
| Waibel M, Solomon VS, Knight DA, et al. (2013) Combined targeting of JAK2 and Bcl-2/Bcl-xL to cure mutant JAK2-driven malignancies and overcome acquired resistance to JAK2 inhibitors. Cell Reports. 5: 1047-59 |
| Xie C, Drenberg C, Edwards H, et al. (2013) Panobinostat enhances cytarabine and daunorubicin sensitivities in AML cells through suppressing the expression of BRCA1, CHK1, and Rad51. Plos One. 8: e79106 |